GLP-1 receptor (GLP-1R) agonists have significant therapeutic effects on non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) in animal models. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.